Quanterix Corporation (NASDAQ:QTRX) is a life sciences company that develops ultra-sensitive digital immunoassay technologies for detecting and measuring biomarkers in blood and other biological samples. Its platform is designed to identify proteins and other biomarkers at concentrations significantly below the capabilities of many conventional immunoassay methods, supporting research into disease biology, diagnosis, treatment development and monitoring.
The company’s primary technology, Simoa, is used in its laboratory instruments, assay kits, consumables and software products. Quanterix offers systems such as the HD-X, SR-X and SP-X platforms, along with assays for applications that include neurology, oncology, immunology, cardiology and infectious disease research. It also provides laboratory services and access to its technology for pharmaceutical, biotechnology, academic and clinical research organizations.
Quanterix was founded in 2007 by David Walt, a scientist and professor associated with Harvard University and the Wyss Institute. The company serves customers internationally through direct operations, commercial partners and distributors. Its corporate headquarters are in Billerica, Massachusetts, and Masoud Toloue serves as president and chief executive officer.
AI Generated. May Contain Errors.
